AI-generated summary
The authors describe a single patient with rheumatoid arthritis who developed osteonecrosis of the jaw about two weeks after starting rituximab, having previously taken risedronate. They suggest rituximab may have been a cause or a factor worsening the condition. The patient was treated conservatively with antiseptic mouth washes, low-level laser treatment and teriparatide, and the authors report complete mucosal coverage after more than two years of follow-up.
- Who or what was studied
- A single patient with rheumatoid arthritis who had previously taken risedronate and developed medication-related osteonecrosis of the jaw after starting rituximab
- Limits stated in the abstract
- The report describes a single case, so no causal conclusion can be drawn about rituximab.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Case report, Low-level laser therapy, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.